Most Read Articles
16 May 2019
Empagliflozin treatment in patients with type 2 diabetes mellitus exerts beneficial effects on cardiovascular (CV) risk factors, including blood pressure and uric acid, according to a systematic review and meta-analysis.
Pearl Toh, 17 May 2019
Metformin continues to protect high-risk individuals from developing type 2 diabetes (T2D) over 15 years, especially among those with higher glycaemic status at baseline and women reporting a history of gestational diabetes mellitus (GDM), according to long-term results from DPP/DPPOS*.
16 May 2019
Due to the increasing global prevalence of obesity, older adults may live more years of their remaining life with limited physical function and activities in daily living (ADLs), according to a study, adding that older adults, their families and healthcare systems should be aware of this problem.
Jairia Dela Cruz, 6 days ago
One anastomosis gastric bypass is as effective as the standard Roux-en-Y procedure in terms of weight loss and metabolic improvements 24 months after the surgery, according to the results of the open-label YOMEGA trial.

Product Highlight - Invokana

16 Dec 2016
INVOKANA – Canagliflozin hemihydrate 100 mg and 300 mg FC tab – Johnson & Johnson (Janssen)
  • INVOKANA demonstrated statistically significant glycated haemoglobin A1c (HbA1c) reductions and helped more patients achieve the ADA-recommended HbA1c goal of <7%1,4.
  • Only Invokana 300 mg demonstrated greater reductions in vs HbA1c sitagliptin 100 mg2.
  • INVOKANA results in the excretion of approximately 77 grams to 119 grams of glucose per day3.
  • INVOKANA provided greater reductions in body weight and systolic blood pressure vs placebo3.
  • INVOKANA showed good tolerability profile with the following most common adverse reactions – female genital mycotic infection, urinary tract infection (UTI) and increased urination3.
References:
1. Stenlöf K, Cefalu WT, Kim KA, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab.2013;15(4):372-382.
2. Schernthaner G, Gross JL, Rosenstock J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care. 2013;36:2508-2515.
3. Invokana_Approved Prescribing Information_Malaysia_EU SmPC vJan2016.
4: American Diabetes Association. Standards of medical care in diabetes—2016. Diabetes Care. 2016; 39(Supplement 1): S39-S46.

Further information is available in Section 11b, New In This Issue and mims.com
Full prescribing information is available upon request.

MKT-CAN-MY-0026Creation Date: October 2016

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
16 May 2019
Empagliflozin treatment in patients with type 2 diabetes mellitus exerts beneficial effects on cardiovascular (CV) risk factors, including blood pressure and uric acid, according to a systematic review and meta-analysis.
Pearl Toh, 17 May 2019
Metformin continues to protect high-risk individuals from developing type 2 diabetes (T2D) over 15 years, especially among those with higher glycaemic status at baseline and women reporting a history of gestational diabetes mellitus (GDM), according to long-term results from DPP/DPPOS*.
16 May 2019
Due to the increasing global prevalence of obesity, older adults may live more years of their remaining life with limited physical function and activities in daily living (ADLs), according to a study, adding that older adults, their families and healthcare systems should be aware of this problem.
Jairia Dela Cruz, 6 days ago
One anastomosis gastric bypass is as effective as the standard Roux-en-Y procedure in terms of weight loss and metabolic improvements 24 months after the surgery, according to the results of the open-label YOMEGA trial.